Combination therapy (osteoporosis)

Osteoporosis drugs generally fall into two groups: antiresorptives, which slow down bone breakdown, and anabolic agents, which stimulate new bone formation. Combination therapy refers to using drugs from both groups together, rather than giving them one after another (which is called sequential therapy). The idea is that building new bone while also slowing its removal might boost bone density more than either approach alone.

This approach is not standard first-line treatment for most people with osteoporosis. It's typically considered only in specific, higher-risk situations, and the evidence on which combinations work best, and for whom, is still evolving. Because anabolic drugs and antiresorptives work through different biological pathways in bone remodeling, combining them adds complexity around timing, cost, side effects, and monitoring.

If combination therapy comes up in conversation with your doctor, it usually reflects a case where fracture risk is considered significant enough to warrant a more aggressive strategy. Decisions about whether to combine medications, which ones, and for how long belong to your prescriber, who will weigh your bone density results, fracture history, and overall health picture before recommending any particular plan.